Claims
- 1. A method for preventing or treating gastrointestinal or systemic diseases in a mammalian subject, comprising:
the step of administering a therapeutically effective amount of a composition comprising adenosine or a prodrug thereof into the peritoneal cavity of said subject at a dose that does not achieve pharmacologically active levels in the aortic arterial plasma of said subject.
- 2. The method of claim 1, wherein said adenosine prodrug is an ester of adenosine.
- 3. The method of claim 2, wherein said ester of adenosine is a phosphate ester of adenosine.
- 4. The method of claim 3, wherein said phosphate ester of adenosine is selected from the group consisting of adenosine-5′-monophosphate, adenosine-5′-diphosphate, adenosine-5′-triphosphate, and adenosine 3′:5′-cyclic monophosphate.
- 5. The method of claim 1, wherein said mammalian subject is a human.
- 6. The method of claim 1, wherein said gastrointestinal disease is associated with inadequate blood flow to said subject's intestines.
- 7. The method of claim 6, wherein said gastrointestinal disease is intestinal hypoperfusion due to hemorrhagic shock of said subject.
- 8. The method of claim 1, wherein said gastrointestinal disease is partial or complete occlusion of mesenteric arterial or venous blood vessels in said subject.
- 9. The method of claim 8, wherein said gastrointestinal disease is thrombosis or embolism of the mesenteric arteries or veins of said subject.
- 10. The method of claim 8, wherein said gastrointestinal disease is atherosclerosis of the mesenteric arterial blood vessels of said subject.
- 11. The method of claim 1, wherein said gastrointestinal disease is necrotizing entrerocolitis of said subject.
- 12. The method of claim 1, wherein said gastrointestinal disease is treated by intestinal transplantation, wherein said step of administration is carried out during said transplantation procedure.
- 13. The method of claim 1, wherein said gastrointestinal disease is traumatic injury to the intestines of said subject.
- 14. The method of claim 1, wherein said gastrointestinal disease is associated with inflammation of the bowel of said subject.
- 15. The method of claim 14, wherein said gastrointestinal disease is Crohn's disease.
- 16. The method of claim 14, wherein said gastrointestinal disease is ulcerative colitis.
- 17. The method of claim 14, wherein said gastrointestinal disease is reperfusion of the bowel of said subject.
- 18. The method of claim 14, wherein said gastrointestinal disease is necrotizing enterocolitis.
- 19. The method of claim 1, wherein said gastrointestinal disease is formation of adhesions in the peritoneal cavity of said subject following abdominal surgery.
- 20. The method of claim 1, wherein said systemic disease is characterized by activation of blood cells which participate in the pathophysiology of said systemic disease in said subject.
- 21. The method of claim 20, wherein said systemic disease is hemorrhagic shock.
- 22. The method of claim 20, wherein said systemic disease is myocardial infarction in said subject.
- 23. The method of claim 20, wherein said systemic disease is stroke in said subject.
- 24. A pharmaceutical composition for treating gastrointestinal or inflammatory diseases in a mammalian subject, wherein said composition comprises adenosine or a prodrug thereof and a pharmaceutically acceptable carrier, and wherein said composition is administered into the peritoneal cavity of said subject at a therapeutically effective dose that does not achieve pharmacologically active levels in the aortic arterial plasma of said subject.
- 25. The pharmaceutical composition of claim 24, wherein said adenosine prodrug is an ester of adenosine.
- 26. The pharmaceutical composition of claim 25, wherein said ester of adenosine is a phosphate ester of adenosine.
- 27. The pharmaceutical composition of claim 26, wherein said phosphate ester of adenosine is selected from the group consisting of adenosine-5′-monophosphate, adenosine-5′-diphosphate, adenosine-5′-triphosphate, and adenosine 3′:5′-cyclic monophosphate.
- 28. The pharmaceutical composition of claim 24, wherein said mammalian subject is a human.
- 29. The pharmaceutical composition of claim 24, wherein said gastrointestinal disease is associated with inadequate blood flow to said subject's intestines.
- 30. The pharmaceutical composition of claim 29, wherein said gastrointestinal disease is intestinal hypoperfusion due to hemorrhagic shock of said subject.
- 31. The pharmaceutical composition of claim 24, wherein said gastrointestinal disease is partial or complete occlusion of mesenteric arterial or venous blood vessels in said subject.
- 32. The pharmaceutical composition of claim 31, wherein said gastrointestinal disease is thrombosis or embolism of the mesenteric arteries or veins of said subject.
- 33. The pharmaceutical composition of claim 31, wherein said gastrointestinal disease is atherosclerosis of the mesenteric arterial blood vessels of said subject.
- 34. The pharmaceutical composition of claim 24, wherein said gastrointestinal disease is necrotizing entrerocolitis of said subject.
- 35. The pharmaceutical composition of claim 24, wherein said gastrointestinal disease is treated by intestinal transplantation, wherein said step of administration is carried out during said transplantation procedure.
- 36. The pharmaceutical composition of claim 24, wherein said gastrointestinal disease is traumatic injury to the intestines of said subject.
- 37. The pharmaceutical composition of claim 24, wherein said gastrointestinal disease is associated with inflammation of the bowel of said subject.
- 38. The pharmaceutical composition of claim 37, wherein said gastrointestinal disease is Crohn's disease.
- 39. The pharmaceutical composition of claim 37, wherein said gastrointestinal disease is ulcerative colitis.
- 40. The pharmaceutical composition of claim 37, wherein said gastrointestinal disease is reperfusion of the bowel of said subject.
- 41. The pharmaceutical composition of claim 37, wherein said gastrointestinal disease is necrotizing enterocolitis.
- 42. The pharmaceutical composition of claim 24, wherein said gastrointestinal disease is formation of adhesions in the peritoneal cavity of said subject following abdominal surgery.
- 43. The pharmaceutical composition of claim 24, wherein said systemic disease is characterized by activation of blood cells which participate in the pathophysiology of said systemic disease in said subject.
- 44. The pharmaceutical composition of claim 43, wherein said systemic disease is hemorrhagic shock.
- 45. The pharmaceutical composition of claim 43, wherein said systemic disease is myocardial infarction in said subject.
- 46. The pharmaceutical composition of claim 43, wherein said systemic disease is stroke in said subject.
RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Application Serial No. 60/200,360 filed on Apr. 28, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60200360 |
Apr 2000 |
US |